Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncothyreon appoints ZymoGenetics' CEO to its board

This article was originally published in Scrip

Executive Summary

The US biotechnology company Oncothyreon has appointed Dr Douglas Williams to its board of directors. Dr Williams is CEO of the biopharmaceutical company ZymoGenetics; he previously held senior positions at Seattle Genetics, Immunex and Amgen. Last December, Oncothyreon announced it was restructuring to focus on small molecules, after being threatened with a Nasdaq delisting in September 2008 for failing to meet a minimum $50 million market value for 10 consecutive days (scripnews.com, December 22nd, 2008). It has since made a number of new senior appointments, including Dr Scott Peterson as vice-president of R&D and Dr Diana Hausman as vice-president of clinical development.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC004919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel